NCT06138132View on ClinicalTrials.gov

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 10, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Multiple SclerosisMultiple Sclerosis, Primary ProgressiveMultiple Sclerosis, Secondary Progressive
Interventions
BIOLOGICAL

KYV-101 anti-CD19 CAR-T cell therapy

KYV-101 anti-CD19 CAR-T cell therapy

DRUG

Standard lymphodepletion regimen

Standard lymphodepletion regimen

Trial Locations (1)

94304

Stanford Multiple Sclerosis Center, Palo Alto

Sponsors

Collaborators (1)

Kyverna Therapeutics
All Listed Sponsors
collaborator

Kyverna Therapeutics

INDUSTRY

lead

Stanford University

OTHER

NCT06138132 - A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis | Biotech Hunter | Biotech Hunter